Vyriad, Inc. logo

Vyriad, Inc.

Vyriad is a clinical stage biotech company that develops smart viral-based oncolytic therapies for the treatment of cancers. It also focuses on developing diagnostic/theranostic tests for accurate prediction of immunovirotherapy response.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://www.vyriad.com
Disease Focus
Development Stage
STOCK CODENon Listed
Address
221 1st Avenue SW Suite 102, MN, 55902
Rochester
United States
Email
Contact Number
+1 888-666-6898

Vyriad partnership agreements include a licensing agreement with MedImmune/AstraZeneca focused on pairing Vyriads oncolytic VSV virus with a checkpoint inhibitor created by MedImmune; and a collaborative research and development agreement with Profectus BioSciences focused on developing oncolytic recombinant VSV vaccines for cancer immunotherapy.

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=” ” connections=”true” suffix=””]

Vyriads oncolytic immunovirotherapy products are based on the companys engineered Oncolytic Vesicular Stomatitus Virus (VSV) and Oncolytic Measles Virus platforms that enable selective destruction of cancer cells without harming normal tissues.

In Jul 2018, Vyriad signs clinical collaboration with Merck KGaA, Germany, and Pfizer to evaluate Oncolytic Virus, Voyager-V1, in combination with Anti-PD-L1 Antibody, Avelumab, in Phase 1 clinical study for Metastatic Colorectal Cancer.

In Aug 2016, StingInn LLC granted Vyriad an exclusive worldwide research license to its StingInns technology for the development of novel recombinant oncolytic viruses encoding STING. In addition to the exclusive license agreement, Vyriad has also secured an equity position in StingInn. Additional details about the agreement were not disclosed.

In Mar 2018, Vyriad raised $9 Mn through secured convertible note financing, with participation by Mayo Clinic, Rochester Area Economic Development, and the Southeast Minnesota Capital Fund.